title: [Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].
abstract: Recently, the significant efficacy of S-1 monotherapy or S-1 plus CDDP combination therapy has been reported. Docetaxel also has been reported to have favorable efficacy in gastric cancer. In addition, docetaxel can be administered in outpatient clinics. We investigated the efficacy and safety of S-1 plus docetaxel combination therapy for 35 naive patients with advanced gastric cancer. Docetaxel was administered at a dose of 40 mg/m(2) on day 1, and oral S-1 was administered at the full dose of 80 mg/m(2) twice daily for two weeks followed by one week rest. MST was 300 days, and the response rate was 42. 9%. Although leucopenia was observed in 31%, all patients were able to be continue this therapy. In conclusion, we considered that this S-1 plus docetaxel combination therapy was effective and safe in advanced gastric cancer, and convenient for outpatients.
authors.affiliation: Dept. of Gastroenterology, Nagoya Daini Red Cross Hospital.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Nishiwaki
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yamada
authors.forename: Keiichirou
authors.initials: K
authors.lastname: Tachi
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Hori
authors.forename: Shuuichirou
authors.initials: S
authors.lastname: Umemura
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yamakawa
authors.forename: Takuya
authors.initials: T
authors.lastname: Kurimoto
authors.forename: Tesshin
authors.initials: T
authors.lastname: Ban
authors.forename: Kei
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Katsumi
authors.initials: K
authors.lastname: Hayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Nemoto
authors.forename: Junko
authors.initials: J
authors.lastname: Shiroko
authors.forename: Etsurou
authors.initials: E
authors.lastname: Orito
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid